Cybrexa Therapeutics

NEWS
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
John Houston brings more than 30 years of experience in drug discovery and development in pharma and biotech as Cybrexa prepares to transition to become a clinical-stage company
CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019
JOBS
IN THE PRESS